Traditional Chinese medicine composition and application thereof

Abstract

The invention provides a traditional Chinese medicine composition and application thereof. The traditional Chinese medicine composition is prepared from angelica sinensis, cynanchum atratum, poria cocos, radix bupleuri, radix paeoniae alba, honey-fried licorice root, moutan bark, fructus gardeniae, mint and rhizoma zingiberis and can be used for treating cancers, and the cancers refer to breast cancers including triple negative breast cancers and estrogen receptor positive breast cancers. The mechanism for treating cancers refers to inhibition of invasion activity and metastasis capability of tumor cells, inhibition of escape of host cell immunosuppression of the tumor cells and reduction of growth and development of the tumor cells. The traditional Chinese medicine composition can be combined with chemotherapeutic drugs for use.

Description

Technical Field

[0001] This invention relates to the field of traditional Chinese medicine technology, and in particular to a traditional Chinese medicine composition and its uses. Background Technology

[0002] The global population suffering from cancer is on the rise, and due to the high mortality rate, cancer treatment is one of the most important issues in modern medicine. Tumor cells metastasize to different tissues and organs during tumor progression. Metastatic tumor cells often become more resistant to treatment and more aggressive. Tumor metastasis is one of the leading causes of death in cancer patients.

[0003] Currently, the main treatments for cancer are surgery, radiation therapy, and drug therapy (including chemotherapy, targeted therapy, and immunotherapy), but each method has its drawbacks. Clinically, surgery or complete removal of tumor tissue is sometimes not feasible. Other methods eventually lead to drug resistance and treatment failure. Many alternative treatments exist worldwide. Cancer patients, especially those in the terminal stage or those who have failed treatment, often resort to alternative medicine. In Asia, cancer patients frequently choose traditional Chinese medicine as a complementary and / or alternative therapy.

[0004] When breast cancer patients choose to take traditional Chinese medicine formulas as a supplement or alternative to conventional Western treatments, Jiawei Xiaoyao San is the most commonly used drug. However, related studies have found that using Jiawei Xiaoyao San alone may increase the risk of metastasis, and more importantly, when used in combination with the chemotherapy drug doxorubicin, it may further enhance the metastatic ability of cancer cells.

[0005] While the original formula of Jiawei Xiaoyao San is widely used, it poses a potential risk factor for cancer patients. Therefore, the important objective of this invention is to address how to modify the formula of Jiawei Xiaoyao San to make it effective for cancer patients and to be used in combination with conventional treatments. Summary of the Invention

[0006] This invention provides a traditional Chinese medicine composition that inhibits tumor cell growth and metastasis by reducing the expression of various proteins related to cancer cell growth and metastasis. Furthermore, this composition can be used in combination with chemotherapy drugs. These effects contribute to cancer treatment.

[0007] The purpose of this invention is to provide a traditional Chinese medicine composition, the raw materials used in the composition being: Angelica sinensis, Cynanchum paniculatum, Poria cocos, Bupleurum chinense, Paeonia lactiflora, Glycyrrhiza uralensis (processed), Paeonia suffruticosa, Gardenia jasminoides, Mentha haplocalyx, and Zingiber officinale (dried).

[0008] To achieve the aforementioned objective, the weight parts of each raw material are as follows: Angelica sinensis 1.6–2.4 parts, Cynanchum atratum 1.6–2.4 parts, Poria cocos 1.6–2.4 parts, Bupleurum chinense 1.6–2.4 parts, Paeonia lactiflora 1.6–2.4 parts, Glycyrrhiza uralensis (processed) 0.8–1.2 parts, Paeonia suffruticosa 1–1.5 parts, Gardenia jasminoides 1–1.5 parts, Mentha haplocalyx 0.8–1.2 parts, and Zingiber officinale (dried) 1.6–2.4 parts by weight.

[0009] To achieve the aforementioned objective, the weight parts of each raw material are as follows: Angelica sinensis 1.8–2.2 parts, Cynanchum atratum 1.8–2.2 parts, Poria cocos 1.8–2.2 parts, Bupleurum chinense 1.8–2.2 parts, Paeonia lactiflora 1.8–2.2 parts, Glycyrrhiza uralensis (processed) 0.9–1.1 parts, Paeonia suffruticosa 1.125–1.375 parts, Gardenia jasminoides 1.125–1.375 parts, Mentha haplocalyx 0.9–1.1 parts, and Zingiber officinale (dried) 1.8–2.2 parts by weight.

[0010] To achieve the aforementioned invention objective, the weight parts of each raw material are as follows: 2 parts Angelica sinensis, 2 parts Cynanchum paniculatum, 2 parts Poria cocos, 2 parts Bupleurum chinense, 2 parts Paeonia lactiflora, 1 part Glycyrrhiza uralensis (processed), 1.25 parts Paeonia suffruticosa, 1.25 parts Gardenia jasminoides, 1 part Mentha haplocalyx, and 2 parts Zingiber officinale (dried).

[0011] Another object of the present invention is to develop the use of the aforementioned traditional Chinese medicine composition for the preparation of cancer treatment drugs.

[0012] To achieve the aforementioned invention objective, the cancer is breast cancer.

[0013] To achieve the aforementioned objective, the breast cancer is triple-negative breast cancer and / or estrogen receptor-positive breast cancer.

[0014] To achieve the aforementioned objectives, the indicators for treating cancer include inhibiting the invasive activity and metastatic ability of tumor cells, inhibiting tumor cells from escaping host cell immune suppression, and reducing the growth and progression of tumor cells.

[0015] To achieve the aforementioned objectives, the traditional Chinese medicine composition can be further used in combination with chemotherapy drugs to inhibit the side effects of chemotherapy drugs.

[0016] To achieve the aforementioned objective, the chemotherapy drug is selected from the group consisting of doxorubicin, 5-fluorouracil, capecitabine, elenodicarb, oxaliplatin, taxane, anthracyclines, cisplatin, alkylating agents, topotecan, and vinca alkaloids.

[0017] In summary, this invention provides a traditional Chinese medicine composition suitable for cancer treatment, which can also be used in combination with chemotherapy drugs. Compared with the current technology, it has the following advantages: (1) It can inhibit the metastatic ability of breast cancer cells, and further reduce the metastatic ability of breast cancer cells induced by chemotherapy drugs. (2) It can inhibit breast cancer cells from escaping the immune suppression of host cells, and further reduce the immune suppression of breast cancer cells induced by chemotherapy drugs. (3) It can reduce the growth and progression of breast cancer cells. (4) It can reduce the metastatic ability of cancer cells induced by chemotherapy drugs. Attached Figure Description

[0018] Figure 1 In the figure A, MCF7 cells were treated with different doses of Atractylodes macrocephala for 24 hours, and the changes in the expression of Zeb1, ER, PD-L1, and zinc finger transcription factor Slug proteins in the cells were identified by Western ink dot immunoassay. Figure 1 In the study, B represents the changes in the expression of Zeb1, ER, PD-L1, and Slug proteins in MCF7 cells treated with different doses of Jiawei Xiaoyao San for 24 hours, which were then identified using Western ink dot immunoassay. Figure 1 In this study, C represents the changes in the expression of Zeb1, PD-L1, and Slug proteins in MDA-MB231 cells treated with different doses of Atractylodes macrocephala for 24 hours, which were identified by Western ink dot immunoassay. Figure 1 In this study, D represents the changes in the expression of Zeb1, PD-L1, and Slug proteins in MDA-MB231 cells treated with different doses of Jiawei Xiaoyao San for 24 hours, identified by Western ink dot immunoassay.

[0019] Figure 2 In the study, A represents the changes in the expression of Zeb1, ER, PD-L1, and Slug proteins in MCF7 cells after treatment with different doses of doxorubicin alone or in combination with 100 μg / ml Jiawei Xiaoyao San for 24 hours, using Western ink dot immunoassay. Figure 2 In this study, B refers to MDA-MB231 cells treated with different doses of doxorubicin alone or in combination with 100 μg / ml Jiawei Xiaoyao San for 24 hours. Changes in the expression of Zeb1 and Slug proteins in the cells were identified using Western ink dot immunoassay.

[0020] Figure 3 In the example A, MCF7 cells were treated with different doses of Baiwei for 24 hours, and the changes in the expression of Zeb1 and ER proteins in the cells were analyzed and identified by Western ink dot immunoassay. Figure 3 In this study, B represents MCF7 cells treated with different doses of a modified formula for 24 hours, and the changes in the expression of Zeb1 and ER proteins were analyzed and identified using Western ink dot immunoassay. Figure 3 In this study, C represents the changes in the expression of Zeb1 and ER proteins in MCF7 cells after treatment with different doses of doxorubicin or a modified formulation of 100 μg / ml for 24 hours, which were then analyzed using Western ink dot immunoassay.

[0021] Figure 4 In this study, A represents the changes in the expression of Zeb1, PD-L1, and Slug proteins in cells after 24 hours of treatment with MDA-MB231 at different doses of a modified formulation, using Western ink dot immunoassay. Figure 4 In this study, B was treated with different doses of doxorubicin alone or in combination with a modified formulation of 100 μg / ml for 24 hours, and the changes in the expression of Zeb1, PD-L1 and Slug proteins in cells were identified by Western ink dot immunoassay.

[0022] Figure 5 In the image, A represents MDA-MB231 cells treated with a drug for 24 hours. Cells with invasive activity that penetrated to the subcellular side were fixed and stained, and then photographed under a microscope at 40x magnification. Figure 5 In this context, B represents the cell count, displayed as mean ± standard deviation. Detailed Implementation

[0023] This invention is a modified formula of Jiawei Xiaoyao San. A preferred embodiment provides a traditional Chinese medicine composition for treating tumors or cancer, the basic ingredients of which are Angelica sinensis, Cynanchum paniculatum, Poria cocos, Bupleurum chinense, Paeonia lactiflora, Glycyrrhiza uralensis (processed), Paeonia suffruticosa, Gardenia jasminoides, Mentha haplocalyx, and Zingiber officinale (dried).

[0024] In one embodiment, the components of the modified traditional Chinese medicine composition are as follows, by weight: Angelica sinensis 1.6-2.4 parts by weight, Cynanchum paniculatum 1.6-2.4 parts by weight, Poria cocos 1.6-2.4 parts by weight, Bupleurum chinense 1.6-2.4 parts by weight, Paeonia lactiflora 1.6-2.4 parts by weight, Glycyrrhiza uralensis (processed) 0.8-1.2 parts by weight, Paeonia suffruticosa 1-1.5 parts by weight, Gardenia jasminoides 1-1.5 parts by weight, Mentha haplocalyx 0.8-1.2 parts by weight, and Zingiber officinale (dried) 1.6-2.4 parts by weight.

[0025] In a preferred embodiment, the components of the modified traditional Chinese medicine composition are as follows, by weight: Angelica sinensis 1.8–2.2 parts by weight, Cynanchum paniculatum 1.8–2.2 parts by weight, Poria cocos 1.8–2.2 parts by weight, Bupleurum chinense 1.8–2.2 parts by weight, Paeonia lactiflora 1.8–2.2 parts by weight, Glycyrrhiza uralensis (processed) 0.9–1.1 parts by weight, Paeonia suffruticosa 1.125–1.375 parts by weight, Gardenia jasminoides 1.125–1.375 parts by weight, Mentha haplocalyx 0.9–1.1 parts by weight, and Zingiber officinale (dried) 1.8–2.2 parts by weight.

[0026] In a preferred embodiment, the components of the modified traditional Chinese medicine composition are as follows, by weight: Angelica sinensis 2 parts, Cynanchum paniculatum 2 parts, Poria cocos 2 parts, Bupleurum chinense 2 parts, Paeonia lactiflora 2 parts, Glycyrrhiza uralensis 1 part, Paeonia suffruticosa 1.25 parts, Gardenia jasminoides 1.25 parts, Mentha haplocalyx 1 part, and Zingiber officinale 2 parts.

[0027] To fully understand the purpose, features, and efficacy of this invention, the content of the traditional Chinese medicine composition described in the above-mentioned preferred embodiment of the modified formulation is provided, and different effective doses are administered to estrogen receptor (ER) positive tubular breast cancer cells and triple-negative basal cell breast cancer cells, respectively. The estrogen receptor-positive tubular breast cancer cells were analyzed using breast cancer cells (MCF7), and the triple-negative basal cell breast cancer cells were analyzed using breast cancer cells (MDA-MB231). Changes in key oncogenic proteins of breast cancer cells were analyzed to demonstrate that the traditional Chinese medicine composition of this embodiment does indeed provide an effect of inhibiting or reducing the activity of breast cancer cells.

[0028] The therapeutic indicators of this invention for cancer treatment include inhibiting the invasive activity and metastatic ability of tumor cells, inhibiting tumor cells from evading host cell immunosuppression, and reducing the growth and progression of tumor cells. The traditional Chinese medicine composition of this invention can be further used in combination with chemotherapy drugs to inhibit the side effects of chemotherapy drugs. The chemotherapy drugs are selected from the group consisting of doxorubicin, 5-fluorouracil, capecitabine, elenodicarb, oxaliplatin, taxane, anthracyclines, cisplatin, alkylating agents, topotecan, and vinca alkaloids.

[0029] Among them, Elenodica can be selected as an anticancer agent; oxaliplatin can be selected as an elopridin; and topotecan can be selected as a topotecan.

[0030] The present invention will be further described in detail below with reference to the accompanying drawings and specific embodiments:

[0031] Example 1: Effects of Traditional Modified Bupleurum and Rambling Powder on Breast Cancer Cells

[0032] Currently, the Modified Bupleurum and Rambling Powder in the related technology or its ingredient Atractylodes macrocephala Koidz. is used alone, and different effective doses are respectively administered to estrogen receptor (ER)-positive tubular breast cancer cells and triple-negative basal cell breast cancer cells. In this experiment, the ER-positive tubular breast cancer cells are used as cell experiments with breast cancer cells (MCF7), and the triple-negative basal cell breast cancer cells are used as cell experiments with breast cancer cells (MDA-MB231). The expressions of metastasis-related proteins Zeb1 (a gene located on chromosome 10) and Slug, the expression of the protein programmed cell death 1 ligand 1 (PD-L1) related to escaping host cell immunosuppression, and the expression of the protein ER related to cancer cell growth in breast cancer cells are analyzed correspondingly, so as to illustrate that the Modified Bupleurum and Rambling Powder in the related technology and Atractylodes macrocephala Koidz. used alone indeed increase the effects of breast cancer cell metastasis, escaping host cell immunosuppression, and cancer cell growth.

[0033] The ingredients of the Modified Bupleurum and Rambling Powder are 2 parts by weight of Angelica sinensis, 2 parts by weight of Atractylodes macrocephala Koidz., 2 parts by weight of Poria cocos, 2 parts by weight of Bupleurum chinense, 2 parts by weight of Paeonia lactiflora Pall., 1 part by weight of roasted licorice, 1.25 parts by weight of Cortex Moutan, 1.25 parts by weight of Gardenia jasminoides Ellis, 1 part by weight of Mentha haplocalyx Briq., and 2 parts by weight of dried ginger.

[0034] Western blot immunoassay was used to identify the effects of Atractylodes macrocephala Koidz. and the formula of Modified Bupleurum and Rambling Powder containing Atractylodes macrocephala Koidz. on protein expression in breast cancer cells MCF7 and MDA-MB231. Among them, Zeb1 and Slug are related to the metastasis ability of tumor cells, PD-L1 is an important protein that helps tumor cells escape host cell immunosuppression, and ER is an estrogen receptor that participates in the growth and progression of breast cancer cells. As Figure 1 shown, both Atractylodes macrocephala Koidz. and the Modified Bupleurum and Rambling Powder containing Atractylodes macrocephala Koidz. increased the content of the four proteins in MCF7 and MDA-MB231 cells. That is, Atractylodes macrocephala Koidz. and the Modified Bupleurum and Rambling Powder containing Atractylodes macrocephala Koidz. will increase the metastasis of breast cancer cells, help breast cancer cells escape host cell immunosuppression, and enhance the growth and progression of breast tumor cells. Therefore, it is not conducive to the treatment of breast cancer.

[0035] Since Jiawei Xiaoyao San is the most commonly used herbal formula for breast cancer patients, this study used Western ink dot immunoassay to determine the effect of combined treatment with the chemotherapy drug doxorubicin on the expression of these proteins. Different effective doses of doxorubicin, alone or in combination with Jiawei Xiaoyao San, were administered to estrogen receptor-positive tubular breast cancer cells and triple-negative basal cell breast cancer cells. In this study, the estrogen receptor-positive tubular breast cancer cells were analyzed using breast cancer cells (MCF7), and the triple-negative basal cell breast cancer cells were analyzed using breast cancer cells (MDA-MB231). The expression of metastatic proteins Zeb1 and Slug, the protein PD-L1 (related to evading host cell immunosuppression), and the growth-related protein ER were analyzed to demonstrate that doxorubicin, alone or in combination with Jiawei Xiaoyao San, does indeed increase breast cancer cell metastasis, evasion of host cell immunosuppression, and cancer cell growth.

[0036] Figure 2 Studies showed that doxorubicin increased the levels of the four proteins mentioned above in MCF7 and MDA-MB231 cells. Jiawei Xiaoyao San further enhanced this effect, particularly on Zeb1 expression in both tumor cell types. In other words, the combined use of chemotherapy drugs with Jiawei Xiaoyao San containing Atractylodes macrocephala increases breast cancer cell metastasis, helps breast cancer cells evade host cell immunosuppression, and enhances the growth and progression of breast tumor cells, thus hindering breast cancer treatment.

[0037] Example 2:

[0038] To evaluate whether other traditional Chinese medicines could replace Atractylodes macrocephala in Jiawei Xiaoyao San for the treatment of breast cancer or other tumors, this invention uses the herb Cynanchum paniculatum to replace Atractylodes macrocephala in Jiawei Xiaoyao San to form the aforementioned improved formula.

[0039] The modified formulation of this invention, using *Cynanchum paniculatum* alone or in combination with doxorubicin, was administered at different effective doses to estrogen receptor (ER)-positive tubular breast cancer cells and triple-negative basal cell breast cancer cells. In this experiment, the estrogen receptor-positive tubular breast cancer cells were tested using breast cancer cells (MCF7), and the triple-negative basal cell breast cancer cells were tested using breast cancer cells (MDA-MB231). The expression of metastatic proteins Zeb1 and Slug, the protein PD-L1 (related to evading host cell immunosuppression), and the growth-related protein ER in breast cancer cells were analyzed to demonstrate that the modified formulation, using *Cynanchum paniculatum* alone or in combination with doxorubicin, effectively reduces breast cancer cell metastasis, evasion of host cell immunosuppression, and cancer cell growth.

[0040] Figure 3 A in the study showed that the expression of Zeb1 and ER in MCF7 cells was inhibited by either Baiwei alone or a modified formulation containing Baiwei. Importantly, the modified formulation also inhibited doxorubicin-induced expression of Zeb1 protein and ER. Figure 3 (C) No expression levels of PD-L1 and Slug proteins were detected in any of the treatments. Zeb1 and Slug are related to the metastatic ability of tumor cells, PD-L1 is an important protein that helps tumor cells evade host cell immunosuppression, and ER is an estrogen receptor involved in the growth and progression of breast tumor cells. Therefore, Baiwei (Radix Cynanchi Atrati) and its modified formula can effectively inhibit the metastasis of breast cancer or tumor cells, reduce the evasion of breast cancer or tumor cells by host cell immunosuppression, and reduce the growth and progression of breast tumor cells, thus benefiting the treatment of breast cancer.

[0041] Further studies have shown that the modified formula containing Cynanchum atratum, used alone or in combination with doxorubicin, has the same effect on MDA-MB231 cells. Figure 4 The results showed that all treatments reduced the protein levels of Zeb1, PD-L1, and Slug in MDA-MB231 cells. Zeb1 and Slug are associated with the metastatic ability of tumor cells, and PD-L1 is an important protein that helps tumor cells evade host cell immunosuppression. Therefore, the modified formulation can effectively inhibit the metastasis of breast cancer or tumor cells and reduce their evasion of host cell immunosuppression, which is beneficial for the treatment of breast cancer or tumors.

[0042] Example 3:

[0043] To evaluate whether the traditional Chinese medicine composition of the present invention can inhibit the invasive activity of breast cancer cells, the invasive activity of MDA-MB231 cells under different treatments was further measured using the Matrigel assay with the aforementioned modified formulation.

[0044] We applied Jiawei Xiaoyao San, a modified formula, and doxorubicin alone or in combination with doxorubicin to triple-negative basal cell carcinoma cells. In this study, we used MDA-MB231 breast cancer cells as the cell line. Invasive cells that penetrated the subcellular side were fixed and stained. The invasive activity of the breast cancer cells was observed and analyzed to demonstrate that the modified formula, used alone or in combination with doxorubicin, reduced the invasive activity of breast cancer cells.

[0045] like Figure 5 As shown, doxorubicin increases the invasive activity of MDA-MB231 cells. The combined treatment of Jiawei Xiaoyao San (containing Atractylodes macrocephala) and doxorubicin further enhanced the invasive activity of MDA-MB231 cells. In contrast, both the modified formula used alone and in combination with doxorubicin significantly inhibited the invasive activity of MDA-MB231 cells.

[0046] In summary, this invention provides a traditional Chinese medicine composition suitable for cancer treatment, comprising Angelica sinensis, Cynanchum paniculatum, Poria cocos, Bupleurum chinense, Paeonia lactiflora, Glycyrrhiza uralensis (processed), Paeonia suffruticosa, Gardenia jasminoides, Mentha haplocalyx, and Zingiber officinale (dried). This composition is suitable for treating breast cancer, particularly triple-negative breast cancer and estrogen receptor-positive breast cancer. Compared to the commonly used cancer medication, Jiawei Xiaoyao San, it has the following advantages:

[0047] (1) The results of the embodiment of reducing Zeb1 and Slug performance have demonstrated that it can inhibit the metastasis of breast cancer cells and reduce the metastasis of breast cancer cells induced by chemotherapy drugs.

[0048] (2) The results of the examples of reducing PD-L1 expression have demonstrated that it can inhibit breast cancer cells from escaping host cell immunosuppression, and can further reduce the escaping of host cell immunosuppression induced by chemotherapy drugs.

[0049] (3) The results of the embodiment that reduced ER performance have demonstrated that it can reduce the growth and progression of breast cancer cells, and can further reduce the growth and progression of breast cancer cells induced by chemotherapy drugs.

[0050] (4) The results of the cell staining and counting examples have shown that the invasive activity of cancer cells can be inhibited, and the invasive activity of cancer cells induced by chemotherapy drugs can be reduced.

[0051] The above description represents the preferred embodiments of the present invention. It should be noted that those skilled in the art can make various improvements and modifications without departing from the principles described in this application, and these improvements and modifications should also be considered within the scope of protection of this application.

Claims

1. A traditional Chinese medicine composition, characterized in that, The raw medicinal materials of the traditional Chinese medicine composition are angelica, baiwei, fuling, chaihu, baishao, zhigancao, mudanpi, zhizi, bohe and ganjiang.

2. The traditional Chinese medicine composition according to claim 1, characterized in that, The weight parts of each raw medicinal material are 1.6-2.4 parts of angelica, 1.6-2.4 parts of baiwei, 1.6-2.4 parts of fuling, 1.6-2.4 parts of chaihu, 1.6-2.4 parts of baishao, 0.8-1.2 parts of zhigancao, 1-1.5 parts of mudanpi, 1-1.5 parts of zhizi, 0.8-1.2 parts of bohe and 1.6-2.4 parts of ganjiang.

3. The traditional Chinese medicine composition according to claim 1, characterized in that, The weight parts of each raw medicinal material are 1.8-2.2 parts of angelica, 1.8-2.2 parts of baiwei, 1.8-2.2 parts of fuling, 1.8-2.2 parts of chaihu, 1.8-2.2 parts of baishao, 0.9-1.1 parts of zhigancao, 1.125-1.375 parts of mudanpi, 1.125-1.375 parts of zhizi, 0.9-1.1 parts of bohe and 1.8-2.2 parts of ganjiang.

4. The traditional Chinese medicine composition according to claim 1, characterized in that, The weight parts of each raw medicinal material are 2 parts of angelica, 2 parts of baiwei, 2 parts of fuling, 2 parts of chaihu, 2 parts of baishao, 1 part of zhigancao, 1.25 parts of mudanpi, 1.25 parts of zhizi, 1 part of bohe and 2 parts of ganjiang.

5. Use of the traditional Chinese medicine composition according to any one of claims 1 to 4, characterized in that, The traditional Chinese medicine composition is used for preparing a medicine for treating cancer.

6. Use according to claim 5, characterized in that, The cancer treated by the medicine for treating cancer is breast cancer.

7. Use according to claim 6, characterized in that, The breast cancer treated by the medicine for treating cancer is triple-negative breast cancer or / and estrogen receptor-positive breast cancer.

8. Use according to claim 7, characterized in that, The medicine for treating cancer is used for inhibiting the invasion activity and metastasis ability of tumor cells, inhibiting tumor cells from escaping from host cell immunosuppression, and reducing the growth and progression of tumor cells.

9. Use according to claim 5, characterized in that, The traditional Chinese medicine composition is also used in combination with a chemotherapy medicine. The chemotherapy medicine is selected from the group consisting of doxorubicin, 5-fluorouracil, capecitabine, elena dodik, oxaliplatin, taxane, anthracycline, cisplatin, alkylating agent, topotecan and vinca alkaloid.

10. Use according to claim 5, characterized in that, The traditional Chinese medicine composition is used for inhibiting the expression of PD-L1 and can be used in combination with immunotherapy.

Images